Article Details

Pandion Therapeutics launches with $58 million for bispecific antibodies

Retrieved on: 2018-01-17 20:33:45

Tags for this article:

Click the tags to see associated articles and topics

Pandion Therapeutics launches with $58 million for bispecific antibodies. View article details on hiswai:

Excerpt

<div>Pandion's series A investors include <b>Polaris Partners</b>, Versant Ventures, Roche Venture Fund, and BioInnovation Capital. The firm is currently headquartered in LabCentral, a shared space for over 30 biotech start-ups in the Cambridge, Mass., biotech hub Kendall Square. Notable LabCentral alumni ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up